[HTML][HTML] Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron
The Omicron (B.1.1.529) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
was initially identified in November 2021 in South Africa and Botswana, as well as in …
was initially identified in November 2021 in South Africa and Botswana, as well as in …
[HTML][HTML] Safety and immunogenicity analysis of a Newcastle disease virus (NDV-HXP-S) expressing the spike protein of SARS-CoV-2 in sprague dawley rats
J Tcheou, A Raskin, G Singh, H Kawabata… - Frontiers in …, 2021 - frontiersin.org
Despite global vaccination efforts, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
continues to evolve and spread globally. Relatively high vaccination rates have been …
continues to evolve and spread globally. Relatively high vaccination rates have been …
[HTML][HTML] Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised …
…, S Slamanig, N Suthepakul, J Tcheou… - …, 2022 - thelancet.com
Background Production of affordable coronavirus disease 2019 (COVID-19) vaccines in low-
and middle-income countries is needed. NDV-HXP-S is an inactivated egg-based …
and middle-income countries is needed. NDV-HXP-S is an inactivated egg-based …
mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations
JM Carreño, G Singh, J Tcheou, K Srivastava… - Vaccine, 2022 - Elsevier
Two messenger RNA (mRNA)-based vaccines are widely used globally to prevent coronavirus
disease 2019 (COVID-19). Both vaccine formulations contain PEGylated lipids in their …
disease 2019 (COVID-19). Both vaccine formulations contain PEGylated lipids in their …
[PDF][PDF] Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer
…, M Saksena, L Sominsky, EM Sordillo, J Tcheou… - Cancer Cell, 2022 - cell.com
During the global pandemic with COVID-19, early reports indicated that cancer patients in
general, and lung cancer patients in particular, who were infected with SARS-CoV-2 had high …
general, and lung cancer patients in particular, who were infected with SARS-CoV-2 had high …
Binding and avidity signatures of polyclonal sera from individuals with different exposure histories to severe acute respiratory syndrome coronavirus 2 infection …
Background The number of exposures to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
and to vaccine antigens affect the magnitude and avidity of the polyclonal …
and to vaccine antigens affect the magnitude and avidity of the polyclonal …
[HTML][HTML] Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized …
…, S Slamanig, JM Carreno, J Tcheou… - Vaccine, 2022 - Elsevier
Production of affordable coronavirus disease 2019 (COVID-19) vaccines in low- and middle-income
countries is needed. NDV-HXP-S is an inactivated egg-based Newcastle disease …
countries is needed. NDV-HXP-S is an inactivated egg-based Newcastle disease …
An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination
JM Carreño, A Raskin, G Singh, J Tcheou… - Science Translational …, 2023 - science.org
NDV-HXP-S is a recombinant Newcastle disease virus–based vaccine against SARS-CoV-2,
which expresses an optimized (HexaPro) spike protein on its surface. The vaccine can be …
which expresses an optimized (HexaPro) spike protein on its surface. The vaccine can be …
[PDF][PDF] SARS-CoV-2-infection-and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase
It is thought that mRNA-based vaccine-induced immunity to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) wanes quickly, based mostly on short-term studies. Here, …
coronavirus 2 (SARS-CoV-2) wanes quickly, based mostly on short-term studies. Here, …
Kinetics and durability of humoral responses to SARS-CoV-2 infection and vaccination
…, C Gleason, B Monahan, G Singh, A Abbad, J Tcheou… - medRxiv, 2023 - medrxiv.org
We analyzed the kinetics and durability of the humoral responses to severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection and vaccination using >8,000 longitudinal …
syndrome coronavirus 2 (SARS-CoV-2) infection and vaccination using >8,000 longitudinal …